WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Daiichi Sankyo

Daiichi SankyoDaiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 17,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to its strong portfolio of medicines for hypertension, dyslipidemia, bacterial infections, and thrombotic disorders, the Group’s research and development is focused on bringing forth novel therapies in cardiovascular-metabolic diseases, pain management, and oncology, including biologics.

www.daiichisankyo.com.

Daiichi Sankyo RSS Channel

Filters
List of articles in category Daiichi Sankyo
Title Published Date
Daiichi Sankyo announces TaNeDS Global 2018 collaborative drug discovery program 26 September 2017
Daiichi Sankyo announces collaborative research on drugs for neglected tropical diseases 30 March 2017
Daiichi Sankyo announces TaNeDS Europe 2017 collaborative drug discovery programme 12 October 2016
Amgen and Daiichi Sankyo announce agreement to commercialize biosimilars in Japan 14 July 2016
Daiichi Sankyo announces commencement of clinical trials in Japan for Duchenne muscular dystrophy treatment 25 February 2016
Daiichi Sankyo signs agreement with Translational Sciences, Inc. to develop and commercialize the first-in-class thrombus dissolving agent, TS23 22 September 2015
Daiichi Sankyo and Ranbaxy launch hybrid business in Brazil to expand business of both companies 17 April 2013
Daiichi Sankyo Establishes New Vaccine Research Unit in Japan 01 November 2011
Daiichi Sankyo & Ranbaxy Announce a New Social Contribution Initiative 31 August 2011
Daiichi Sankyo and Ranbaxy to Integrate New Drug Research and Development System 05 July 2010
Ranbaxy Launches Antiplatelet Agent Prasugrel in India 10 June 2010
Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient™ 13 July 2009
DAIICHI SANKYO continues its expansion in Germany and Europe 21 August 2008
DAIICHI SANKYO acquires osteoporosis medication EVISTA® from Lilly 07 March 2008

Business & Industry

  • Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform
  • BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
  • Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma
  • AstraZeneca launches call for entries to the 2023 global R&D Postdoctoral Challenge
  • Pfizer invests $43 billion to battle cancer

Research & Development

  • 'Biohybrid' device could restore function in paralysed limbs
  • Scientists use tardigrade proteins for human health breakthrough
  • DNA treatment could delay paralysis that strikes nearly all patients with ALS
  • Scientists reveal a potential new approach to treating liver cancer
  • Normalizing tumor blood vessels may improve immunotherapy against brain cancer
  • Engineered bacteria find tumors, then alert the authorities
  • First nasal monoclonal antibody treatment for COVID-19 shows promise for treating virus, other diseases

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  • FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
  1. You are here:  
  2. Home
  3. Daiichi Sankyo

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.